BioSpace News Archive

Biotech Bay

SUPIRA MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS NEXT GENERATION PERCUTANEOUS VENTRICULAR ASSIST DEVICE

Supira Medical, Inc. announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay.

September 16, 2022
·
3 min read
Genetown

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection.

September 16, 2022
·
11 min read
Genetown

Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development

Astria Therapeutics, Inc. today announced that the Company will host a virtual R&D Day titled “Update on STAR-0215 and Its Clinical Development for the Prevention of HAE Attacks” on September 30th from 10:30am to 12:00pm ET.

September 16, 2022
·
1 min read
Biotech Bay

Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

Quince Therapeutics, Inc. today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida.

September 16, 2022
·
4 min read
Biotech Bay

Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit.

September 16, 2022
·
1 min read
Drug Development

Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. today announces that the Company will present updated clinical data on its Phase 1 Danon Disease Trial for RP-A501 during an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 to be held Sept. 30 – Oct. 3, 2022.

September 16, 2022
·
5 min read
FDA

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients.

September 16, 2022
·
10 min read
Biotech Beach

DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) Gene Signature Testing for Systemic Lupus Erythematosus Patients

The DxTerity IFN-1 gene signature test is for patients with Systemic Lupus Erythematosus (SLE or lupus), a chronic autoimmune disease affecting up to 1 million patients in the US.

September 16, 2022
·
2 min read
BioCapital

Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older

Novavax, Inc. today announced that the Israel Ministry of Health has granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid.

September 16, 2022
·
11 min read
BioCapital

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has granted expanded emergency use authorization (EUA) for Nuvaxovid.

September 16, 2022
·
11 min read